jRCT2031240659招募中不适用
MEGLUDASE for Intravenous Use 1000 General Drug Use-Results Survey (All-case surve ) (MEGLUDASE for Intravenous Use 1000 General Drug Use-Results Survey (All-case surve ))
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •All patients who received meglutase for detoxification during delayed methotrexate excretion due to methotrexate/leucovorin rescue therapy
排除标准
- •Patients with a history of severe hypersensitivity to the components of meglutase
结局指标
主要结局
-
Safety(incidence of side effects,etc.)
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia ARoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia AJPRN-UMIN000048156Chugai Pharmaceutical Co. Ltd.150
招募中
不适用
HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors).Hemophilia AJPRN-UMIN000032515Chugai Pharmaceutical Co. Ltd.100
已完成
1 期
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple SclerosisMultiple SclerosisNCT01745783Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud26
已完成
不适用
HEMLIBRA Subcutaneous injection Special Drug Use Surveillance (with Hemophilia A without Inhibitors).Hemophilia AJPRN-UMIN000037503Chugai Pharmaceutical Co. Ltd.87
进行中（未招募）
不适用
Administration of drugs intramuscular: in the buttocks region and the side region of the hipsyphilisRBR-3fgtdpniversidade Federal de Alagoas